[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-cognitive-impairment":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,219,0,25,[9,48,81,106,139,167,194,211,242,266,288,315,350,372,400,422,452,478,504,523,546,566,600,627,655],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100605983","pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-disease-ad-or-mild-cognitive-impairment-mci-100605983",false,"NCT07169630","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)","* INCLUSION CRITERIA:\n\nParticipants will be referred by a physician with the suspected diagnosis of AD or MCI. However, the PI of this protocol will provide the final diagnosis. For this reason, this protocol will have just one consent form for participants suspected of having either AD or MCI.\n\nAD and MCI Study Groups:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n* Have been diagnosed by a neurologist or psychiatrist with MCI or AD.\n* Be in good general health as evidenced by medical history and physical examination.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nHealthy Volunteers:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Able to provide informed consent.\n* Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth the study groups will be excluded if they meet any of the following criteria:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Participants should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n* Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the volunteer and\u002For caregiver during the screening visit.\n* Participants must not have substance use disorder or alcohol use disorder.\n* Participants should not be under treatment or previously treated with an amyloid antibody such as lecanemab.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n* Pregnancy or breast feeding.\n* HIV infection.\n* Non-English speaking participants.\n\nExclusion of Children:\n\nInclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.\n\nExclusion of Pregnant or Breastfeeding Women:\n\nPregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will not require contraception for this protocol to allow participants autonomy in medical decision-making. However, while we will not require contraception for woman of childbearing potential, we will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant\n\nExclusion of Participants who are HIV Positive:\n\nPersons with HIV infection are excluded because HIV infection itself may change cAMP signaling.\n\nExclusion of Non-English-Speaking Participants:\n\nNon-English-speaking participants will be excluded from participation in this study because neuropsychological testing is required by this protocol. This testing, which is critical for interpreting study results, has not been validated in other languages or when using a translator.",true,"ALL","50 Years","100 Years",{"count":22,"type":23},90,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","Background:\n\nAbout 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.\n\nObjective:\n\nTo test whether medical imaging using a new radiotracer (\\[18F\\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.\n\nEligibility:\n\nPeople aged 50 years and older with AD or MCI. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have up to 5 clinic visits with 3 imaging scans of the brain.\n\nThey will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.\n\nParticipants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.\n\nParticipants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....",[29,30,31],"Alzheimer s Disease","Mild Cognitive Impairment","Healthy",[33,34],"18F-PF-06445974","PET Imaging","RECRUITING","2026-08-20",{"date":38,"type":39},"2026-08-21","ACTUAL",{"date":41,"type":23},"2026-08-26",{"date":43,"type":23},"2030-04-11",{"name":45,"class":46},"National Institute of Mental Health (NIMH)","NIH",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100388301","enhancing-outcomes-in-cognitive-impairment-through-use-of-home-sleep-apnea-testing-100388301","NCT04335994","ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing","ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing: A Randomized Controlled Trial (ENCHANT Study)","ENCHANT","Inclusion Criteria:\n\n* Evidence of cognitive impairment by any one of: (i) Montreal Cognitive Assessment (MoCA) score of 13-28, or (ii) Mini Mental State Examination (MMSE) score of 18-30, or (iii) Toronto Cognitive Assessment (TorCA) score ≤281.\n* A diagnosis of: (i) Single-domain amnestic or multiple cognitive domain (with one feature being amnestic) Mild Cognitive Impairment due to Alzheimer's disease (AD); or (ii) Probable AD dementia; or (iii) Possible AD dementia due to limited concomitant cerebrovascular disease; or (iv) Probable Vascular dementia or Vascular Mild Cognitive Impairment, as per the 2011 American Heart Association Scientific Statement; or (v) Patients with a suspected neurodegenerative condition known to be associated with non-OSA sleep disorders (e.g. Parkinson's disease-related dementia and dementia with Lewy Bodies); and\u002For (vi) Mixed disease\n* Have the competency to provide informed consent, or the availability of a substitute decision maker\u002Fcaregiver who can provide consent (if needed).\n* The availability of a caregiver to assist in the completion of HSAT or iPSG, if needed.\n\nExclusion Criteria:\n\n* Prior diagnosis of OSA within the last 2 years\n* Patients already using CPAP or a dental appliance for previously diagnosed OSA.\n* A known contraindication for the use of the HSAT that will be used in this study: (a) Moderate to severe pulmonary disease or congestive heart failure that could compromise the validity of the HSAT results (in users of the ApneaLink); (b) Permanent pacemaker or history of sustained non-sinus cardiac arrhythmia (in users of the WatchPAT).\n* Any medical device that would interfere with the placement of the HSAT\n* Significant physical impairment or language barrier that would restrict the ability to use the HSAT or complete the study assessments.",{"count":57,"type":23},200,[59],"NA","Obstructive sleep apnea (OSA), which causes abnormal pauses in breathing during sleep, is common in patients with vascular cognitive impairment (VCI) and Alzheimer's disease (AD), and exacerbates the cognitive deficits seen in these conditions. OSA is typically treated with continuous positive airway pressure (CPAP), which has been shown to improve cognition in VCI and slow cognitive decline in AD. Despite the need to identify OSA in patients with VCI\u002FAD, these patients often do not undergo testing for OSA. One major barrier is that in-laboratory polysomnography (iPSG), the current standard for diagnosing OSA, is inconvenient for patients with VCI\u002FAD who may be reliant on others for care or require familiar sleep environments. A convenient and cheaper alternative to iPSG is home sleep apnea testing (HSAT), which has been validated against iPSG to diagnose OSA and has proven feasible for use in VCI\u002FAD. Our primary objective is to determine whether the use of HSAT is superior to iPSG in terms of the proportion of patients who complete sleep testing by 6 months post-randomization. We will also investigate cost-effectiveness, patient satisfaction, proportion of patients treated with CPAP, changes in cognition, mood, sleep-related and functional outcomes between HSAT and iPSG at 6 months.",[62,63,64,30,65,66,67],"Obstructive Sleep Apnea","Alzheimer Disease","Vascular Dementia","Parkinsons Disease With Dementia","Dementia With Lewy Bodies","Mixed Dementia",[62,69,70,71],"Cognitive Impairment","Home Sleep Apnea Test","Screening","2026-08-19",{"date":36,"type":39},{"date":75,"type":39},"2019-09-23",{"date":77,"type":23},"2027-06",{"name":79,"class":80},"Sunnybrook Health Sciences Centre","OTHER",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":24,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100501598","center-for-research-and-education-on-aging-and-technology-enhancement---create-v---project-1-100501598","NCT05811338","Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1","Center for Research and Education on Aging and Technology Enhancement - CREATE V","Inclusion Criteria:\n\n* 65+ years of age\n* Able to read English at the 6th grade level\n* Have 20\u002F60 vision with or without correction.\n\nExclusion Criteria:\n\n* Blind or have visual impairments that limit their ability to view the technology.\n* Deaf or have hearing impairments that limit their ability to answer telephone queries.\n* Have a life-limiting\u002Fterminal illness\n* Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand\n* Chronic neck pain\u002Finjury that might make the headset uncomfortable","60 Years",{"count":90,"type":23},108,[59],"Project 1: The goal of this research project is to examine usability and acceptance of virtual reality (VR) applications and their efficacy with older adults. This highly innovative cross-site Stage 1 Intervention Development Project (NIH (National Institutes of Health) Stage Model) will apply the CREATE systematic approach to the design and evaluation of an immersive VR program, Cognitive Activity Social Technology (CAST), for older adults. The program will provide a suite of virtual cognitive, social and activity engagement applications; and allow for virtual interactions.",[30],[95],"Technology","NOT_YET_RECRUITING","2026-08-18",{"date":36,"type":39},{"date":100,"type":23},"2026-10-31",{"date":102,"type":23},"2027-05-31",{"name":104,"class":80},"Weill Medical College of Cornell University",3,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":115,"conditions":116,"keywords":121,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":47},"100652450","a-mobile-informatics-solution-to-assist-caregivers-in-care-coordination-and-monitoring-social-engagement-100652450","NCT07773493","A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement","Inclusion Criteria:\n\n* Persons with memory concerns must be English speaking.\n* Persons with memory concerns must self-report a healthcare provider visit due to memory concerns or memory related diagnosis by a physician or other qualified health care provider consistent with having mild-to-moderate memory impairment.\n* Persons with memory concerns must be over the age of 65.\n* Persons with memory concerns must be able to formally consent or assent to participate in the study.\n* Persons with memory concerns must have internet access.\n* Care partners of persons with memory concerns must speak English.\n* Care partners must be 18 years of age and over.\n* Care partners must self-identify as the primary caregiver for the person with memory concerns.\n* Care partners must indicate a willingness to use the Social Reminder System as well as to being randomized to a control group.\n* Care partners must have a mobile phone with internet access in order to install and use the care partner app.\n\nExclusion Criteria:\n\n* Those who do not meet the criteria above will be excluded.\n* Persons with memory concerns with severe or no dementia are not eligible.\n* Individuals who score below 6 and above 24 on the TICS-40 will not be eligible.","18 Years",{"count":57,"type":23},[59],"This study will evaluate the Social Reminder System, a mobile informatics system designed to support persons with memory concerns and their care partners. The system is intended to aid social integration for persons with memory concerns and improve care coordination and reduce caregiver burden among caregivers.\n\nResearchers will enroll 100 persons with memory concerns and their care partners. Half of the dyads will be randomly assigned to receive the Social Reminder System technology for a 6-month period, and the other half will be randomly assigned to the usual care control group. Participants will complete baseline, 3-month, and 6-month surveys. A subset of participants who receive the technology will also be asked to complete a semi-structured interview after the 6-month survey.",[117,30,118,119,120],"Memory Disorders","Dementia","Social Isolation","Caregiver Burden",[122,123,124,125,126,127,128,129,130],"Social Reminder System","SRS","Persons with memory concerns","Social engagement","Mobile health","Care coordination","Alzheimer's disease and related dementias","Mild-to-moderate memory impairment","Caregiver stress","2026-08-14",{"date":72,"type":39},{"date":134,"type":23},"2026-11-01",{"date":136,"type":23},"2028-06",{"name":138,"class":80},"University of Minnesota",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":17,"sex":18,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":24,"phases":151,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100424234","phase-2-senicapoc-in-alzheimers-disease-100424234","NCT04804241","Senicapoc in Alzheimer's Disease","Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease","Senicapoc","Inclusion Criteria:\n\n* Age 55-85\n* Fluent in either English or Spanish\n* Willing to be randomized to active drug (10 mg Senicapoc) vs. placebo (3:1 ratio)\n* Clinical Dementia Rating (CDR) global score of 1 or 0.5\n* Education adjusted scores between 12-28 on the Montreal Cognitive Assessment (MoCA) at the Screening visit.\n* A consensus clinical diagnosis of either amnestic Mild Cognitive Impairment (MCI) or mild AD dementia. Diagnoses are made by a comprehensive case conference review for all participants in the ADRC longitudinal cohort and all CADC referrals, resulting in a consensus diagnosis made according to current research criteria. For patients referred from other clinics, the case will be reviewed by a study physician and neuropsychologist and only patients who satisfy criteria for probable AD (McKhann et al 1984) or amnestic MCI (Petersen et al 2004) will be eligible for enrollment.\n* Vision (with or without correction) of at least 20\u002F50 for distant vision\n* All participants will need a study partner informant who has at least 6 hours of contact per week with the participant. The study partners are used to help answer questions on the subject's behalf, since many of them will be impaired and may need assistance with providing accurate information. The study partners are not asked to provide any opinions or judgements about the subjects.\n* For Females of childbearing potential: Must agree to practice a highly effective method of contraception throughout the study until completion of the Week 78 follow up visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of less than 1% per year when used correctly and consistently.\n\nExclusion Criteria:\n\n* Unstable medical illnesses including hepatic insufficiency (elevated ALT, AST, or GGT; or low albumin attributable to liver disease), renal insufficiency (CK-EPI stage 4 or higher, or estimated GFR \\\u003C30)\n* Unstable ischemic cardiovascular disease, respiratory failure, moderate or severe congestive heart failure - New York Heart Association class III or IV, cancer, unstable hematologic disease or a life expectancy of \\\u003C3 years\n* Use of experimental AD treatments\n* Unable to undergo MRI scanning (e.g. pacemaker, metallic implants, severe claustrophobia)\n* History of chronic psychiatric illness (e.g. schizophrenia), any episode of major depression within last 2 years, or current Geriatric Depression Scale (GDS) \\> 6, any recent suicide attempts or suicidal ideation. Subjects with a diagnosis of bipolar disorder may be included if they have been clinically stable for a minimum of 3 years prior to the Screening visit. Clinical stability to be determined by the Principal Investigator.\n* History of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis), head trauma resulting in any persistent cognitive deficit\n* History of alcohol or drug abuse\u002Fdependence within the past 5 years\n* Known allergy to chemically related compounds (e.g. clotrimazole)\n* Lack of good venous access, such that multiple blood draws would be precluded\n* Regular use of any of these CNS active medications: benzodiazepines, antipsychotics, narcotics, or anti-epileptic drugs. Exceptions may be allowed by the Principal Investigator for regular use of low doses of CNS active medications. Subjects using any of these treatments will be instructed to hold their dose on the evening prior and the day of the efficacy visits (Baseline, Week 26 and Week 52). Stable doses (\\> 6 weeks) of cholinesterase inhibitors or memantine will be allowed, as will stable doses of anti-depressants.\n* Female subjects who are pregnant or breastfeeding or who plan to become pregnant during participation in this trial\n* Inability to swallow oral tablets\n\nExclusions for Cerebrospinal Fluid (CSF) Sub-study:\n\n* Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter\n* History of bleeding diathesis or coagulopathy,\n* On anticoagulant therapy (within 14 days of lumbar puncture (LP), including but not limited to warfarin, heparin, dabigatran, rivaroxaban, and apixaban,\n* Requires daily antiplatelet therapy, including but not limited to aspirin (unless \\\u003C 81mg\u002Fday), clopidogrel, dipyridamole, and ticlopiidinegrel. However, the investigators will not exclude those who can safely hold antiplatelet therapy for 7 days prior to LP. Safety will be determined by the participant's Primary Care Provider and study PI.\n* For those who take antiplatelet therapy intermittently (e.g. aspirin as needed for pain), the investigators will exclude any doses within 48 hours of the LP or more than two dosses within 7 days of LP.\n* platelet count less than the lower limit of normal (platelet counts between 100,000 and 150,000 mm3 are permissible as long as the investigator confirms there is no evidence of current bleeding diathesis or coagulopathy)\n* The investigators will require INR\u002FPT and aPTT labs to be done within 14 days of LP and will exclude those with INR \\> 1.30 or abnormally elevated aPTT.\n\nExclusions for PET Sub-Study:\n\n* Does not have good venous access, such that multiple blood draws would be precluded\n* Prior radiation exposure of \\> 2 rem total within last 12 months.\n* Probable AD dementia patients with a global cortical SUVr \\\u003C 1.08.","55 Years","85 Years",{"count":150,"type":23},55,[152],"PHASE2","Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.",[30,63],[156,157,145],"Amnestic Mild Cognitive Impairment (MCI)","Mild AD dementia",{"date":159,"type":39},"2026-08-17",{"date":161,"type":39},"2022-03-18",{"date":163,"type":23},"2027-12",{"name":165,"class":80},"University of California, Davis",2,{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":17,"sex":18,"minAge":112,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":178,"conditions":179,"keywords":183,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":47},"100392965","phase-1-pet-imaging-of-cyclooxygenases-in-neurodegenerative-brain-disease-100392965","NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","* INCLUSION CRITERIA:\n\nPatients: In order to be eligible to participate in this study, patients must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n3. Have been diagnosed by a neurologist or psychiatrist with MCI, ALS, PD, or an adult onset neurodegenerative dementia, such as AD (including amyloid negative subjects), FTD, corticobasal syndrome, or Huntington s disease.\n4. Be in good general health as evidenced by medical history and physical examination.\n5. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n6. Agree to adhere to the lifestyle considerations.\n\nHealthy volunteers: In order to be eligible to participate in this study, healthy volunteer subjects must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Female participants of childbearing potential must be using a medically acceptable means of contraception\n3. Able provide informed consent.\n4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n5. Be enrolled in 01-M-0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies\n6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n7. Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth patients and healthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL\n2. Subjects should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAID) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n3. Contraindications to ketoprofen, such as hypersensitivity to ketoprofen or history of upper or lower gastrointestinal bleeding.\n4. Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n5. Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n6. Are unable to travel to the NIH.\n7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n8. Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the patient and\u002For caregiver during the screening visit.\n9. Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life.\n10. Participants should not be under treatment with Aduhelm, nor should they have been treated in the past.\n11. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n12. Pregnancy\n13. HIV infection\n14. Be NIMH staff or an NIH employee who is a subordinate\u002Frelative\u002Fco-worker of the investigators.","99 Years",{"count":176,"type":23},184,[26],"Background:\n\nAbout 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.\n\nObjective:\n\nTo learn whether COX-1 and\u002For COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.\n\nEligibility:\n\nAdults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.\n\nParticipants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.\n\nParticipants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.\n\nParticipants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.",[180,118,181,182,30],"Parkinson's Disease","Alzheimer's Disease","ALS",[34,184,185,118,186,182,187],"PD","Inflammation","Cyclooxygenase-2","MCI",{"date":159,"type":39},{"date":190,"type":39},"2021-08-17",{"date":192,"type":23},"2030-10-03",{"name":45,"class":46},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":86,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":17,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":209,"leadSponsor":210,"locationsCount":105},"100630287","center-for-research-and-education-on-aging-and-technology-enhancement---create-v---project-2-100630287","NCT07485712","Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2","Inclusion Criteria:\n\n* 62+ years of age\n* Able to read English at the 6th grade level\n* Have 20\u002F60 vision with or without correction.\n* Clinical diagnosis of mild cognitive impairment (MCI)\n* Subjective cognitive complaints\n* Evidence by clinical evaluation\n* Clinical Dementia Rating Global scale of 0.5-2.0\n* Probable MCI\n* Montreal Cognitive Assessment (MoCA) score of 18-26\n* No major Instrumental activities of daily living (IADL) impairments\n* Geriatric Depression Scale of 4 or Below\n* No diagnosis of dementia\n\nExclusion Criteria:\n\n* Blind or have visual impairments that limit their ability to view the technology.\n* Deaf or have hearing impairments that limit their ability to answer telephone queries.\n* Have a life-limiting\u002Fterminal illness\n* Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand\n* Cognitive impairment (MOCA ≤ 25)",{"count":201,"type":23},120,[59],"The goal of this Stage 1 (NIH Stage Model) Intervention Development cross-site project is to develop, using a user-centered design approach, and evaluate an innovative intelligent adaptive software package aimed at providing cognitive and social support and engagement to older adults with mild cognitive impairment (MCI). The system will be designed to adapt to the needs and abilities of the user. The investigator's goal is to develop a unique and highly innovative technology tool that can provide adaptive support to aging individuals with MCI, even as cognition might deteriorate further. Speech data collected as part of an embedded reminiscence feature will advance fundamental knowledge of how speech and language production data might serve as an early indicator of cognitive decline.",[30],[95],"2026-08-13",{"date":159,"type":39},{"date":100,"type":23},{"date":102,"type":23},{"name":104,"class":80},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":17,"sex":18,"minAge":219,"maxAge":4,"enrollmentInfo":220,"targetDuration":222,"studyType":223,"phases":4,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":47},"100550540","multimodal-assesment-of-alzheimer-patients-100550540","NCT06448403","Multimodal Assesment of Alzheimer Patients","Multimodal Assessment of Cognitive Impairment in Alzheimer Patients","MultiAD","Inclusion Criteria:\n\n* MCI and AD according to relevant ICD-criterias.\n* Control cohort is age and gender matched with other cohorts.\n\nExclusion Criteria:\n\n* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)\n* AD diagnosis before the age of 65 (Early-onset AD).\n* Brain tumor\n* Traumtic head injury\n* Earlier neurosurgery\n* Other neyrodegenerative diseases (i.e Parkinson and ALS)\n* Diseases related to inflammation and auto-immunity (i.e MS)","65 Years",{"count":221,"type":23},60,"5 Years","OBSERVATIONAL","The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).\n\nThe main questions the study aims to answer are:\n\n1. What findings can be used to earlier detect patients that will develop Alzheimers?\n2. Which differences are seen between healthy and cognitively impaired patients?\n3. Which differences are seen between patients with Alzheimers disease?\n\nParticipants will undergo:\n\n* Cognitive tests\n* Magnetic resonance imaging (MRI)\n* Electroencephalography (EEG)\n* Blood sample collection\n* Fecal sample collection\n* A randomized group will undergo polysomnography analysis.",[30,226,69,118],"Alzheimer Disease, Late Onset",[228,229,230,231,232,118,233],"Alzheimer Disease (AD)","Mild cognitive impairment (MCI)","Brain Diseases","Nervous System Disorders","Neurodegenerative Diseases","Cognitive impairment","2026-08-12",{"date":206,"type":39},{"date":237,"type":39},"2024-07-01",{"date":239,"type":23},"2030-12-29",{"name":241,"class":80},"Norwegian University of Science and Technology",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":24,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":105},"100524755","otc-hearing-aid-and-mci-100524755","NCT06112860","OTC Hearing Aid and MCI","Over-the-counter Hearing Aids and Mild Cognitive Impairment","Inclusion Criteria:\n\n* Over 60 years of age\n* Mild dementia or mild cognitive impairment. Diagnosis will be made at participating memory evaluation centers (see recruitment).\n* Mild to moderate bilateral hearing loss and no current hearing aid use.\n* A communication partner who is able and willing to participate in the study.\n* No vision impairment that would interfere with the ability to complete study tasks (i.e., legally blind, severe cataracts, or macular degeneration)\n* Able to provide own consent as evaluated by the Consent Assessment\n\nExclusion Criteria:\n\n1. Clinically significant unstable or progressive medical conditions, or conditions which, in the opinion of the investigator(s) places the participant at unacceptable risk if he or she were to participate in the study.\n2. History of unresolved communication difficulties following another neurological problem (i.e., stroke or brain tumor), neurodevelopmental disorder (i.e., Down's syndrome), or head\u002Fneck cancer\n3. Positive history of major psychiatric disorder (i.e., schizophrenia, significant untreated depression)\n4. Co-enrolled in other intervention studies targeting hearing, language, or communication strategies.\n5. History or current fluctuating hearing loss","90 Years",{"count":251,"type":23},50,[59],"The goal of this study is to better understand if, in patients with mild to moderate hearing loss who are also experiencing mild cognitive impairment (MCI) or Alzheimer's disease and related dementias (ADRD), Over-the-Counter (OTC) hearing aids:\n\n1. improve communication\n2. Whether the magnitude of benefit depends on the patient's level of cognitive disability,\n3. Whether alternative remediation (such as targeted communication strategies) offer similar benefits.\n\nParticipants and a communication partner will be randomized into an OTC first or Communication Strategies first arm, where participants will receive communication strategy information customized for those with cognitive impairment.",[255,30,256],"Hearing Loss","Alzheimer Disease and Related Dementias (ADRD)",[258],"Over-the-counter Hearing Aids",{"date":131,"type":39},{"date":261,"type":39},"2024-07-23",{"date":263,"type":23},"2027-03-30",{"name":265,"class":80},"Northwestern University",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":17,"sex":18,"minAge":219,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":24,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":47},"100518208","phase-2-the-mito-frail-trial-effects-of-mitoq-on-vasodilation-mobility-and-cognitive-performance-in-frail-older-adults-100518208","NCT06027554","The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults","Mito-Frail","Inclusion Criteria:\n\n* men and women aged 65-80 with a slow gait speed (0.4m\u002Fs based on a 4m walk) and\u002For mild cognitive impairment.\n* good cardiovascular health (not taking any blood pressure\u002Fflow\u002Fmetabolism altering medications)\n\nExclusion Criteria:\n\n* A vaccination in past two weeks\n* Recent acute infection three weeks prior to enrollment\n* Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy\n* Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids\n* Severe autoimmune disease requiring biological therapy\n* Major severe illness and\u002For Hospitalization in past 3 months\n* On warfarin or other medications that are considered a blood thinner\n* Recent fall or other conditions that will impair ability to complete and\u002For interpret mobility performance test\n* Known bleeding disorder\n* Any conditions that would impair the function to perform grip strength test\n* include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.\n* Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)\n* Baseline ECG QTc \\>450 ms in men and QTc \\>460 ms in women\n* Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)","80 Years",{"count":221,"type":23},[152],"The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and\u002For cognitive dysfunction. The main question\\[s\\] it aims to answer are:\n\n* To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction\n* To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels\n* To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.",[278,30,279],"Frailty","Aging","2026-08-10",{"date":234,"type":39},{"date":283,"type":39},"2024-10-07",{"date":285,"type":23},"2028-02-01",{"name":287,"class":80},"UConn Health",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":17,"sex":18,"minAge":112,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":24,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":47},"100474635","neuromodulation-of-memory-in-aging-100474635","NCT05460468","Neuromodulation of Memory in Aging","Adaptive Neuromodulation of Working Memory Networks in Aging and Dementia","TMS-AD","Inclusion Criteria:\n\n* English Speaking\n* Willing to provide consent\n\nExclusion Criteria:\n\n* History of any Axis I DSM-V disorder, excluding major depressive disorder or generalized anxiety disorders\n* Current history of substance abuse or dependence (excluding nicotine)\n* Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes), cardiac pacemakers, or vagus Nerve stimulation device\n* Increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, increased intracranial pressure, or history of significant head trauma with loss of consciousness for ≥ 5 minutes.\n* Neurological disorder including, but not limited to: space occupying brain lesion; any history of seizures, history of cerebrovascular accident; fainting, cerebral aneurysm, Dementia, Hungtington chorea; Multiple Sclerosis.\n* Current use of medications known to lower the seizure threshold and\u002For affect working memory","75 Years",{"count":298,"type":23},150,[59],"The proposed research will use closed-loop transcranial magnetic stimulation (TMS) based on individualized brain networks to establish parameters that can reliably control brain states. This will be tested in healthy aging and mild cognitive impairment (MCI) cohorts. The investigators will study network activation and neural oscillatory mechanisms underlying the network that regulates working memory and then target this network using closed-loop TMS to the Prefrontal Cortex. Investigators will measure the impact of TMS on working memory performance and task-based neural activity. The project will use brain stimulation and network modeling techniques to enhance working memory in healthy older adults and MCI and will demonstrate the value of closed-loop, network-guided TMS for future clinical applications.",[30,187],[303,304,305],"TMS","Transcranial Magnetic Stimulation","Memory","2026-08-07",{"date":308,"type":39},"2026-08-11",{"date":310,"type":39},"2024-03-28",{"date":312,"type":23},"2027-06-30",{"name":314,"class":80},"Indiana University",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":18,"minAge":322,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":24,"phases":325,"briefSummary":326,"conditions":327,"keywords":331,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":105},"100649253","prevalence-of-mild-cognitive-impairment-and-dementia-in-patients-admitted-to-non-neurological-rehabilitation-wards-100649253","NCT07731334","Prevalence of Mild Cognitive Impairment and Dementia in Patients Admitted to Non-neurological Rehabilitation Wards","COGinREHAB","Inclusion Criteria:\n\n* Age ≥45 years\n* Hospitalization for at least 7-10 days for a non-neurological condition, in cardiac, pulmonary, or orthopedic intensive rehabilitation units, or intermediate care units\n* Adequate fluency in the Italian language\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Illiteracy\n* Severe, uncorrected visual impairment and\u002For hearing loss\n* Severe verbal communication deficit\n* Inability to remain seated for the duration of the assessment\n* Inability to use the dominant upper limb\n* Altered state of consciousness or alertness (e.g., delirium)\n* Severe scalp skin lesions or dermatitis precluding electrode application for neurophysiological recordings\n* Previous or current history of severe psychiatric disorders (e.g., psychotic disorders, bipolar disorder, severe major depressive disorder with psychotic symptoms, current suicidal risk, or other psychiatric conditions judged by the investigator to interfere with study participation, procedural compliance, or interpretation of results)\n* Previous history or current presence of clinically relevant neurological pathologies other than cognitive impairment (e.g., epilepsy, stroke, neurodegenerative diseases such as Parkinson's disease or multiple sclerosis, moderate-to-severe traumatic brain injury, brain tumors, central nervous system infections, or other neurological conditions that may influence cognitive, behavioral, or neurological functioning, or otherwise compromise the study objectives)","45 Years",{"count":324,"type":23},384,[59],"Cognitive impairment is common among older adults hospitalized for non-neurological conditions but often goes unrecognized, particularly in rehabilitation settings where clinical attention is mainly focused on physical recovery. The COGinREHAB study is a multicenter, prospective, longitudinal interventional study conducted at three rehabilitation centers of the Fondazione Don Carlo Gnocchi in Italy (Florence and Milan).\n\nThe study will enroll 384 patients aged 45 years or older who are hospitalized for at least 7-10 days in cardiac, pulmonary, or orthopedic intensive rehabilitation units, or in intermediate care units, for conditions unrelated to the nervous system.\n\nAt admission, all participants undergo a clinical and cognitive screening visit. Patients whose screening results suggest possible cognitive impairment then undergo a more extensive neuropsychological evaluation. In those with confirmed cognitive impairment, additional blood tests are performed to measure biomarkers of neurodegeneration (GFAP, neurofilament light chain, and phosphorylated tau-217), together with APOE genotyping and a non-contrast brain CT scan. In a subset of these patients, resting-state EEG, auditory event-related potentials, actigraphy, and overnight polysomnography are also performed. Patients with confirmed cognitive impairment are invited to a follow-up visit 12 months later to assess whether their cognitive profiles and biological markers have changed.\n\nThe main purpose of the study is to estimate how frequently cognitive impairment occurs among patients admitted to non-neurological rehabilitation units, including how often it was previously undiagnosed. The study will also describe the clinical, biological, and neurophysiological profile of these patients and examine how cognitive impairment evolves over one year.",[187,328,30,329,330],"Mild Cognitive Impairment (MCI)","Cognitive Deficit","Cognitive Decline",[30,332,333,334,118,335,336,337,338,339,340,341],"Cognitive Screening","Multimodal Assessment","Cognitive Trajectories","Non-Neurological Rehabilitation","Plasma Biomarkers","Neurodegeneration","Neurophysiological Measures","Longitudinal Study","APOE Genotype","MoCA","2026-08-05",{"date":280,"type":39},{"date":345,"type":39},"2026-01-20",{"date":347,"type":23},"2028-12",{"name":349,"class":80},"Fondazione Don Carlo Gnocchi ETS",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":18,"minAge":147,"maxAge":249,"enrollmentInfo":357,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":371},"100611340","neuclare-device-for-temporary-improvement-of-executive-function-in-patients-with-mild-cognitive-impairment-and-prodromal-alzheimers-disease-100611340","NCT07239310","Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease","A Prospective, Multicenter, Randomized, Double-Blind, Parallel-Group, Confirmatory Clinical Trial to Verify the Efficacy and Safety of the Cognitive Improvement Effect on Executive Function in Medication-Treated Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease Using the Neuclare Physical Device for Medical Use","Inclusion Criteria:\n\n1. Adults aged 55 to 90 years.\n2. Diagnosed with mild cognitive impairment (MCI) or early Alzheimer's disease according to the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria.\n3. mild cognitive impairment\u002Fvery mild Alzheimer's disease with CDR 0.5-1 and MMSE-II ≥18.\n4. On stable cognitive therapy medications for at least 1 month.\n5. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with structural brain lesions detected on brain MRI (e.g., cerebral edema, intracerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.).\n2. Patients with uncontrolled metabolic disorders such as thyroid dysfunction, hypoglycemia, or hepatic\u002Frenal impairment, or those on long-term medications that may cause cognitive impairment (e.g., anticholinergic drugs).\n3. Patients with a history of epileptic seizures, depression, or psychiatric disorders; patients experiencing visual hallucinations or fluctuating cognitive decline.\n4. Patients with psychiatric disorders outside of the inclusion criteria.\n5. Patients with a history of severe diseases such as cancer or tuberculosis.\n6. Patients with a history of or currently taking psychoactive drugs or medications affecting the central or peripheral nervous system.\n7. Patients with contact dermatitis or other skin hypersensitivity conditions.\n8. Patients with fever ≥ 40°C as measured by tympanic temperature.\n9. Patients who have experienced bleeding within the past 3 months due to procedures or surgeries that may affect vital signs.\n10. Patients unable to undergo MRI.\n11. Pregnant patients.\n12. Patients with clinical brain calcification observed on computed tomography (CT) scans.\n13. Patients with known allergies to contrast agents such as Definity or Gadovist.\n14. Any other condition deemed by the investigator to make participation in the clinical trial inappropriate.",{"count":358,"type":23},138,[59],"This study is a multicenter, randomized, double-blind, parallel-group, prospective confirmatory clinical trial designed to evaluate whether the Neuclare medical device can temporarily improve executive function (planning and problem-solving abilities) in adults with mild cognitive impairment or very early Alzheimer's disease.\n\nParticipants will continue their current medication and be randomly assigned to receive either the Neuclare device (treatment group) or a sham device (control group). The device will be applied to the brain three times per week for four weeks. Both participants and study staff are blinded to the group assignment. Safety and adverse events will be closely monitored throughout the study.\n\nDuring the trial, assessments will include attention, cognitive function, daily living activities, brain imaging (Amyloid PET-CT), blood biomarkers, and quality of life (EQ-5D-5L).\n\nThe goal of this study is to determine whether the Neuclare device, in combination with standard medication, can safely provide temporary improvements in executive function.",[30,362],"Alzheimer's Disease(AD)",{"date":306,"type":39},{"date":365,"type":39},"2025-11-20",{"date":367,"type":23},"2027-01",{"name":369,"class":370},"Deepsonbio","INDUSTRY",7,{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":382,"briefSummary":383,"conditions":384,"keywords":388,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":4},"100650328","cognitive-intervention-for-cognitive-impairment-100650328","NCT07747675","Cognitive Intervention for Cognitive Impairment","Cognitive Intervention to Improve Mild Cognitive Impairment in Older Adults: Randomized Double-blind Clinical Trial","Inclusion Criteria:\n\n* Affiliation with IMSS Aguascalientes Family Medicine Unit (UMF) No. 7; age 65 to 95 years; male or female; known diagnosis of type 2 diabetes mellitus; any level of education; any occupation; presence of mild cognitive impairment; availability to attend cognitive intervention sessions; and signing of informed consent.\n\nExclusion Criteria:\n\n* Patients with disabling hearing and\u002For visual impairments, patients with paralysis, and patients with severe psychiatric illness.","95 Years",{"count":381,"type":23},102,[59],"Mild cognitive impairment is characterized by cognitive dysfunction without impairment in instrumental activities of daily living, with aging being the primary risk factor. Cognitive interventions employ stimulation and training techniques to address this impairment.\n\nObjective: To determine the effect of a cognitive intervention on mild cognitive impairment in older adults with type 2 diabetes mellitus.\n\nMethods: A double-blind, randomized clinical trial involving 102 patients, who will be assigned to either a control group or an intervention group. Data collection will utilize a sociodemographic profile questionnaire and the Montreal Cognitive Assessment (MoCA). The cognitive intervention will be implemented over an average period of two months per subgroup, consisting of eight weekly, 60-minute sessions. Analysis will be conducted using descriptive statistics, and a linear mixed-effects model for repeated measures will be applied to evaluate the intervention's effect.",[385,30,386,387],"Cognitive Intervention","Elderly Adults","Diabetes Mellitus",[30,389,390,387],"Cognitive intervention","Elderly adults","2026-07-31",{"date":342,"type":39},{"date":394,"type":23},"2026-08-03",{"date":396,"type":23},"2026-10-15",{"name":398,"class":399},"Instituto Mexicano del Seguro Social","OTHER_GOV",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":17,"sex":18,"minAge":147,"maxAge":249,"enrollmentInfo":406,"targetDuration":4,"studyType":223,"phases":4,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":47},"100380860","autoimmune-features-of-neurodegenerative-disorders-100380860","NCT04239079","Autoimmune Features of Neurodegenerative Disorders","PD and age matched controls:\n\nFor PD participants (n=30):\n\nInclusion criteria:\n\n* Clinical diagnosed PD based on UK Brain Bank criteria for the clinical diagnosis of PD. And must demonstrate two of the following three, as modified from BioFIND criteria: rest tremor, rigidity, or bradykinesia, with dopaminergic medication benefit\n* Age at recruitment ≥ 55\n* Age at motor onset \\> 45\n* PD onset age between 50-75 years\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Atypical features indicative of a Parkinson-Plus disorder (Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD)) including cerebellar signs, supranuclear gaze palsy, apraxia and other cortical signs, or prominent autonomic failure, neuroleptic treatment at time of onset of parkinsonism, active treatment with a neuroleptic at time of study entry, history of repeated strokes with stepwise progression of parkinsonism, history of repeated head injury, history of definite encephalitis, prominent gait imbalance early in the course (\\\u003C 5 years)\n* History of Dementia\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent.\n\nFor age-matched control participants (n=30):\n\nInclusion criteria:\n\n* Ages ≥55 years old\n* With lack of PD in first-degree blood relatives\n* Montreal Cognitive Assessment (MoCA): ≥26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent\n\nAD\u002FaMCI and age matched controls:\n\nFor AD\u002FaMCI participants (n=30):\n\nInclusion criteria:\n\n* Clinically diagnosed mild AD\u002Famnestic MCI. The severity will be accessed through the Clinical Dementia Rating Scale (CDR). CDR equal to 0.5 or 1 will be necessary to meet criteria. Participants with advanced AD stage will not be capable to give their consent.\n* Age ≥55 years old\n* Mini-Mental State Exam (MMSE): 20-26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Other forms of dementia including frontotemporal dementia or other dementia associated with parkinsonism such as Dementia with Lewy bodies (DLB), or Parkinson's disease Dementia (PDD), Progressive Supranuclear Palsy or corticobasal degeneration.\n* History of Parkinson's disease (PD)\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent\n\nFor age-matched control participants (n=30):\n\nInclusion criteria:\n\n* Healthy volunteers ≥55 years old\n* CDR: 0\n* MoCA: ≥26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* History of Parkinson's disease (PD)\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent",{"count":201,"type":23},"This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD\u002FAmnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immune response in PD and AD.\n\nThe study involves up to two study visits involving brief questionnaires and blood draw of up to 250cc (approximately 17 tablespoons) to be collected. More ways to participate, including 1) smaller amount blood donation (up to 100cc per visit for 1-2 visits); and 2) participation via tele-visit and mobile phlebotomy visits (blood donation up to 50cc, \\~5 tubes, by a certified mobile phlebotomist at home\u002Flocation of choice) now available.",[409,63,30],"Parkinson Disease",[411,412,413,30],"Autoimmune features","Parkinson's disease","Alzheimer's disease",{"date":415,"type":39},"2026-08-04",{"date":417,"type":39},"2019-05-01",{"date":419,"type":23},"2028-07",{"name":421,"class":80},"Columbia University",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":24,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":105},"100649605","binaural-beats-for-cognitive-function-in-older-adults-with-mild-cognitive-impairment-in-nursing-homes-100649605","NCT07735910","Binaural Beats for Cognitive Function in Older Adults With Mild Cognitive Impairment in Nursing Homes","The Effect of Binaural Beats on Cognitive Function in Older Adults With Mild Cognitive Impairment in Nursing Homes: A Randomized Controlled Trial","BB-MCI","Inclusion Criteria:\n\n1. Age 60 years or older.\n2. Not previously diagnosed with dementia.\n3. Meets the diagnostic criteria for mild cognitive impairment, with Montreal Cognitive Assessment scores adjusted by education level, Mini-Mental State Examination score \\>= 24, and Activities of Daily Living score \\\u003C 23.\n4. Has lived in a nursing home for more than 2 months and plans to continue living there during the study period.\n5. No hearing impairment; Hearing Handicap Inventory for the Elderly-Screening Version score \\\u003C 8, and able to hear binaural beats through both ears.\n6. Conscious and able to cooperate with questionnaires and scale assessments.\n7. Has not taken medications that may affect cognitive function within 3 to 6 months before the intervention.\n\nExclusion Criteria:\n\n1. Severe physical disease, major organ failure, or advanced malignant tumor.\n2. Diagnosed depression or other psychiatric disorders.\n\nWithdrawal Criteria:\n\n1. Serious adverse events during the study, such as falls, disease recurrence, discomfort caused by the intervention audio, death, or other conditions making continued participation unsuitable.\n2. Voluntary withdrawal from the study.\n\nRemoval Criteria:\n\n1. Incomplete data resulting in missing information.\n2. Missing three or more intervention sessions within 2 weeks without following intervention instructions.\n3. Receiving other treatments or interventions related to cognitive function during the trial.",{"count":221,"type":23},[59],"This study will evaluate whether binaural beats can improve cognitive function in older adults with mild cognitive impairment living in nursing homes. Participants will listen to 10-Hz alpha-frequency binaural beats through headphones once daily for 30 minutes for 14 consecutive days. Cognitive function, sleep quality, anxiety, and depressive symptoms will be assessed before the intervention, after the intervention, and at a 2-week follow-up after the intervention. The study aims to determine whether binaural beats are a safe, simple, and non-drug approach to support cognitive health in older adults with mild cognitive impairment.",[30,434],"Cognitive Function",[436,437,438,434,439,440,441,442],"Binaural Beats","Older Adults","Nursing Homes","Sleep Quality","Anxiety","Depression","Non-drug Intervention","2026-07-27",{"date":445,"type":39},"2026-07-30",{"date":447,"type":39},"2026-06-15",{"date":449,"type":23},"2026-09-20",{"name":451,"class":80},"China Medical University, China",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":249,"enrollmentInfo":459,"targetDuration":4,"studyType":24,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":47},"100521697","phase-2-commets--combination-mci-metabolic-syndrome-100521697","NCT06072963","COMMETS- Combination MCI Metabolic Syndrome","Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study","Inclusion Criteria:\n\n* Diagnosis of MCI (based on a MOCA \\\u003C27 and a clinical dementia rating scale \\[CDR\\] score of 0.5 representing questionable dementia).\n* Diagnosis of MetS -requiring a) abdominal obesity (waist circumference \\>102cm for men and \\>88cm for women), and b) glucose intolerance (fasting glucose\\>110 mg\u002FdL) and at least one of the following-c) dyslipidemia (high triglycerides \\[\\>150 mg\u002FdL\\] and low HDL \\[\\\u003C40mg\u002FdL for men and \\\u003C50 mg\u002FdL for women\\]), or d) elevated blood pressure (\\>130\u002F\\>85 mmHg).\n* Fluent in Hebrew\n* The study requires an active study partner\n\nExclusion Criteria:\n\n* Diabetes (of any type)\n* Taking medications that may affect glucose metabolism (including a GLP-1RA).\n* Diagnosis of dementia and its subtypes, conditions that may directly affect cognition,\n* short life expectancy or a medical condition that precludes consistent participation in the study,\n* contraindications to either insulin or Semaglutide.\n* Medications that may affect glucose metabolism such as corticosteroids.",{"count":460,"type":23},80,[152],"The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive Impairment), who are enriched for cerebrovascular disease and at high dementia risk. The study will focus on cognitive and biological outcomes, allowing identification of relevant mechanisms.",[63,30,464],"Metabolic Syndrome",[466,30,467,118,468,469],"Alzheimer disease","Metabolic syndrome","Semaglutide","Intranasal insulin","2026-07-23",{"date":443,"type":39},{"date":473,"type":39},"2024-01-30",{"date":475,"type":23},"2028-12-01",{"name":477,"class":80},"Rutgers, The State University of New Jersey",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":24,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":47},"100623480","sleepsmart-for-veterans-with-insomnia-and-mild-cognitive-impairment-100623480","NCT07397182","SleepSMART for Veterans With Insomnia and Mild Cognitive Impairment","SleepSMART for Veterans With Insomnia and Mild Cognitive Impairment: A Randomized Clinical Trial","SleepSMART","Inclusion Criteria:\n\n* Veterans\n* chart diagnosis MCI\n* DSM-5 diagnosis of insomnia and an Insomnia Severity Index (ISI) score \\>7 at baseline\n* ability to understand, speak, and read English with acceptable visual and auditory acuity\n* stable on medications for at least 4 weeks prior to enrollment\n\nExclusion Criteria:\n\n* presence of neurological disorders such as Parkinson's disease or seizures, dementia (based on chart diagnosis or clear evidence of dementia at the baseline neuropsychological testing using DSM5 criteria for Major Neurocognitive Disorder)\n* and\u002For history of moderate to severe TBI (determined by medical record or self-report of \\>30 minutes loss of consciousness)\n* schizophrenia, psychotic disorder, and\u002For bipolar disorder\n* untreated or poorly managed medical conditions that may impact sleep, including thyroid disease, nocturia, chronic respiratory or heart disease, or diabetes\n* untreated obstructive sleep apnea and\u002For sleep disturbances other than insomnia\n* current substance use disorder with \\\u003C30 days abstinence\n* suicidality greater than mild risk as measured by the Columbia-Suicide Severity Rating Scale\n* exposure to therapist directed (individual or group) CBT-I within the past year",{"count":298,"type":23},[59],"Insomnia is a transdiagnostic health problem affecting the physical, cognitive, emotional, and social functioning of Veterans. Importantly, chronic insomnia may be a modifiable risk factor for progression to serious health conditions, such as mild cognitive impairment (MCI) and dementia. Sleep Symptom Management and Rehabilitation Therapy (SleepSMART) was developed as an adapted form of Cognitive Behavioral Therapy for Insomnia (CBT-I) specifically designed for older Veterans with cognitive impairments. SleepSMART focuses on enhancing CBT-I by providing supportive cognitive strategies to boost treatment learning and adherence. In a recent pilot investigation, SleepSMART was found to be feasible, acceptable, and demonstrated preliminary efficacy among a sample of Veterans with co-morbid insomnia and MCI. This proposed investigation aims to conduct a randomized controlled trial investigating the effectiveness of SleepSMART, compared to standard CBT-I in older Veterans with insomnia and MCI.",[490,30],"Insomnia",[492,490,30,493,494],"Veterans","Sleep treatment","Cognitive functioning","2026-07-21",{"date":470,"type":39},{"date":498,"type":23},"2026-11-02",{"date":500,"type":23},"2030-03-31",{"name":502,"class":503},"VA Office of Research and Development","FED",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":17,"sex":18,"minAge":147,"maxAge":273,"enrollmentInfo":511,"targetDuration":4,"studyType":223,"phases":4,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":47},"100523959","mci-speech-in-noise-100523959","NCT06102486","MCI Speech in Noise","Speech Perception in Noise as an Improved Marker for Neurocognitive Dysfunction","Inclusion Criteria:\n\n* Adults diagnosed with or suspected to have MCI (for MCI group) or are cognitively normal (for Control group)\n* Absence of other risk factors that might affect CAP (Central Auditory Processing) performance (e.g., active ear infections, congenital developmental delay, severe hearing loss)\n* Age 55-80\n* Normal hearing sensitivity (\\\u003C40 dB HL Pure Tone Average (average of 500, 1000, 2000 Hz) thresholds bilaterally\n* Normal middle ear function defined by tympanometry (0.3-2.0 ml)\n* Native English speaker\n\nExclusion Criteria:\n\n* Active ear infections or abnormal middle ear pathology\n* Other health condition prohibiting the completion of the CAP test battery\n* Mild to profound peripheral hearing loss (\\>40 dB (decibel) HL (hearing loss) Pure Tone Average (average of 500, 1000, 2000 Hz) bilaterally\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* History of CNS (Central Nervous System) disorder that might severely impact cognitive function (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, neurosyphilis, intracranial tumors, history of significant head trauma with loss of consciousness (≥30 min), and cerebrovascular disease)\n* Severe mental illness (e.g., schizophrenia, bipolar disorder)\n* Current, uncontrolled medical condition that could affect cognition (e.g., hypertension)\n* History of substance use disorder within the (other than nicotine\u002Fcaffeine)\n* Non-correctable severe hearing or vision loss\n* Use of \"Cognition Enhancing Drugs\"\n* Frequent, severe headaches (occasional headaches or migraines are fine)",{"count":512,"type":23},70,"The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their brain understands and processes sound. The investigators are also evaluating, within those with MCI, whether the hearing tests are associated with neurocognitive functioning. The investigators are interested in learning whether changes in cognition in those with MCI can be detected using tests of how the brain processes sound. The investigators hypothesize that participants with MCI will score worse on both hearing tests and neurocognitive tests than participants without MCI. Participants are asked to complete multiple types of hearing tests, take a series of neurocognitive tests, and complete a few questionnaires.",[30],{"date":516,"type":39},"2026-07-22",{"date":518,"type":39},"2024-05-18",{"date":520,"type":23},"2026-09-02",{"name":522,"class":80},"Dartmouth-Hitchcock Medical Center",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":24,"phases":531,"briefSummary":532,"conditions":533,"keywords":534,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":166},"100469702","improve-new-learning-and-memory-in-individuals-with-mild-cognitive-impairment-100469702","NCT05396248","Improve New Learning and Memory in Individuals With Mild Cognitive Impairment","Use of a Memory Technique to Improve New Learning and Memory in Individuals With Mild Cognitive Impairment","Inclusion Criteria:\n\n* 60 or older.\n* read and speak English fluently.\n* Research based diagnosis of Amnestic Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* prior stroke or neurological injury\u002Fdisease (i.e. traumatic brain injury, Multiple Sclerosis, or Stroke).\n* history of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis).\n* significant alcohol or drug abuse history (inpatient treatment).\n* Benzodiazepines and steroid use",{"count":201,"type":23},[59],"The current study is a double-blind, placebo-control randomized clinical trial examining the efficacy of memory retraining in individuals with Mild Cognitive Impairment (MCI). Impairment in higher level cognitive processing, such as new learning and memory, is one of the most common deficits in individuals with MCI and such deficits have been shown to exert significant negative impact on multiple aspects of everyday life, including occupational and social functioning. Despite these findings, few studies have attempted to treat these cognitive deficits in order to improve the everyday functioning of individuals with MCI. Through a small randomized clinical trial, the investigators found that individuals with MCI with documented cognitive impairment show a significant improvement in their memory performance following a treatment protocol designed to facilitate learning. The current proposal will replicate this finding and further evaluate (a) the impact of the treatment on everyday functioning, (b) the long term efficacy of the treatment and (c) the utility of booster sessions in facilitating long-term treatment effects. We will randomly assign older individuals who meet criteria for a diagnosis of amnestic MCI to a memory retraining group or a placebo control group. Both groups will undergo baseline, immediate and long-term follow-up assessment consisting of: (1) a traditional neuropsychological battery, (2) an assessment of global functioning examining the impact of the treatment on daily activities, and (3) functional neuroimaging. This design will allow the investigators to evaluate the efficacy of this particular memory retraining technique in an aMCI population through the assessment of cognitive function via a standard evaluation. In addition, the investigators will be able to draw conclusions regarding the impact of this particular memory remediation program on everyday life from questionnaires completed by the participant and a significant other. Optional enrollment in pre- post neuroimaging will also allow the investigators to look at changes in the brain.",[30],[305,535,536,537,538],"learning","rehabilitation","aging","cognition",{"date":516,"type":39},{"date":541,"type":39},"2023-06-28",{"date":543,"type":23},"2027-03",{"name":545,"class":80},"Kessler Foundation",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":24,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":564,"locationsCount":47},"100611670","improving-neurological-health-with-acetylcholine-via-neuroplasticity-based-computerized-exercise-in-mild-cognitive-impairment-100611670","NCT07243600","Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment","Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment (INHANCE-MCI)","INHANCE-MCI","Inclusion Criteria:\n\n1. Potential participant must be 65 years or older at the time of study screening.\n2. Potential participant must have MCI as defined by:\n\n   * Total score between 18-26 inclusive on the Montreal Cognitive Assessment (MoCA)\n   * Cognitive concern by participant, informant, or clinician and evidence of preserved functional abilities as defined as a Clinical Dementia Rating (CDR) of 0.5 with a memory score of 0.5 or 1.\n3. Potential participant must have a study partner\u002Finformant defined as any acquaintance (e.g., family member, friend, neighbor, clinician) who has regular (at least monthly) interactions (in person or remote) with the participant.\n4. If potential participant reports use of medications typically prescribed for dementia such as, but not limited to, Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, Aducanumab, Leqembi or Lecanemab, Donanemab, the dose must be stable for at least 12 weeks prior to study enrollment.\n5. Potential participant must demonstrate adequate decisional capacity, in the judgment of the investigator, and capable of to making an informed decision regarding their participation in this research study.\n6. Potential participant must be likely able to complete all study activities and outcome measures in the judgment of the investigator.\n7. Potential participant must have the visual, auditory, and motors capacity to use the computerized intervention in the judgment of the investigator.\n8. Potential participant must be able to communicate in either English or French.\n\nExclusion Criteria:\n\n1. Potential participant has an existing diagnosis of major neurocognitive disorder at screening (DSM-IV).\n2. Potential participant who answered 'yes' to question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS or 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS \"Suicidal Behavior\" if the ideation or behavior occurred within 2 months from Participant's date of consent (as recommended by the FDA for treatment trials.)\n3. Potential participant scores \\>10 on the Geriatric Depression Scale - Short Form (GDS-SF).\n4. Potential participant has previously completed 10 or more hours of the computerized cognitive intervention program manufactured by Posit Science.\n5. Potential participant is participating in a concurrent clinical trial (involving an investigational pharmaceutical, behavioral treatment, medical device or other) that, in the judgment of the investigator, could affect the outcome of this study.\n6. Potential participant is pregnant or breastfeeding.\n7. Potential participant has claustrophobia or implantation with any medical devices above the waist that may concentrate radio frequency fields or have other medical issues that may frustrate participation in MRI\u002FPET imaging procedures.\n8. Potential participant has a history of large vessel stroke with significant residual motor or cognitive impairment.\n9. Potential participant has a history of moderate to severe traumatic brain injury with residual cognitive symptoms.\n10. Potential participant has a history of brain tumor.\n11. Potential participant has a congestive heart failure diagnosis.\n12. Potential participant has a primary diagnosis of idiopathic Parkinson's disease.\n13. Potential participant has multiple sclerosis or Amyotrophic lateral sclerosis diagnosis.\n14. Potential participant has evidence of a non-neurodegenerative neurological disorder that would interfere with the ability to carry out study activities.\n15. Potential participant has has evidence of any other unstable medical conditions that would interfere with the ability to carry out study activities or cause fluctuations in cognition (for example, but not limited to, unstable diabetes, chronic obstructive pulmonary disorder dependent on oxygen).\n16. Potential participant has any other clinically significant or unstable medical condition (for example, but not limited to, ongoing alcohol dependency or drug abuse, schizophrenia, psychosis) that in the investigator's opinion would interfere with the ability to carry out study activities.\n17. Potential participant is undergoing or plans to undergo surgery requiring anesthesia, chemotherapy, or radiation treatment in the six months following screening (can be rescreened and enrolled later).",{"count":555,"type":23},84,[59],"This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).",[30],"2026-07-20",{"date":516,"type":39},{"date":562,"type":23},"2026-07-17",{"date":102,"type":23},{"name":565,"class":370},"Posit Science Corporation",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":18,"minAge":574,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":223,"phases":4,"briefSummary":577,"conditions":578,"keywords":580,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":47},"100648037","blood-tests-for-alzheimers-disease-can-plasma-biomarkers-diagnose-and-predict-disease-progression-100648037","NCT07717567","Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression","The Diagnostic and Prognostic Role of Plasma Biomarkers in Alzheimer's Disease","BLAD","Inclusion Criteria (main study and sub-study):\n\n1. Age greater than or equal to 40 years (patients of childbearing age are admitted).\n2. Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.\n3. Mini-Mental State Examination (MMSE) score greater than or equal to 18.\n\n   Additional inclusion criterion for the validation sub-study:\n4. Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.\n\nExclusion Criteria (main study):\n\n1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.\n2. Pregnancy or breastfeeding.\n3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.\n4. Subjects who require a legal guardian or tutor.\n\nExclusion Criteria (validation sub-study):\n\n1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.\n2. Pregnancy.\n3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.\n4. Subjects who are unable to give informed consent and require a legal guardian or tutor.","40 Years",{"count":576,"type":23},2000,"BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\n2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.\n\nThe study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.",[63,30,579,118,69],"Subjective Cognitive Decline",[413,581,582,583,584,585,586,587,588,30,579,118,589,590,591],"Plasma biomarkers","pTau-181","Abeta42","Abeta40","NfL","GFAP","sTREM2","ApoE","Blood biomarkers","Diagnostic accuracy","Prognosis","2026-07-16",{"date":495,"type":39},{"date":595,"type":39},"2023-09-12",{"date":597,"type":23},"2032-06-01",{"name":599,"class":80},"IRCCS San Raffaele",{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":18,"minAge":147,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":24,"phases":609,"briefSummary":610,"conditions":611,"keywords":616,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":621,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":625,"locationsCount":47},"100473568","phase-2-pathways-relating-amnestic-mci-to-a-mild-traumatic-brain-injury-history-100473568","NCT05446584","Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History","PATH","Inclusion Criteria:\n\n1. Active diagnosis of amnestic mild cognitive impairment\n2. Presence of an mTBI history for the mTBI+ group; absence of an mTBI history for a control sample\n3. Female and male subjects\n4. All races\u002Fethnicities\n5. Age 55 years and older\n6. Fluent in English\n\nExclusion Criteria:\n\n1. Mild traumatic brain injury within past year\n2. Lifetime history of moderate or severe brain injury\n3. Lifetime major neurologic syndromes (e.g., stroke, epilepsy, brain tumor)\n4. Lifetime major cardiovascular conditions (e.g., heart attack, heart failure)\n5. Current substance use disorder\n6. Current major psychiatric disorders (e.g., major depressive disorder, bipolar disorder)\n7. Current vision or hearing impairment that interferes with testing\n8. Any electronic and or metallic implants in the skull or brain\n9. Current medication use known to alter HD-tDCS reactivity",{"count":608,"type":23},75,[152],"This study will probe if the biological changes in amnestic mild cognitive impairment (aMCI) are related to a history of mild traumatic brain injury (mTBI) using high definition transcranial direct current stimulation (HD-tDCS) and blood-derived biomarker tools. Participants who Do as well as those who Do Not have a history of mTBI will be enrolled in the study.",[30,612,613,614,615],"Amnestic Mild Cognitive Disorder","Amnestic Mild Cognitive Impairment","Mild Traumatic Brain Injury","Concussion, Brain",[187,617,618,619,620],"TBI","memory","biomarker","Alzheimer",{"date":559,"type":39},{"date":623,"type":39},"2023-04-20",{"date":102,"type":23},{"name":626,"class":80},"University of Texas Southwestern Medical Center",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":174,"enrollmentInfo":635,"targetDuration":4,"studyType":24,"phases":636,"briefSummary":637,"conditions":638,"keywords":640,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":166},"100610959","sensory-enrichment-using-aromatherapy-for-neurobehavioral-and-psychological-symptoms-in-early-dementia-100610959","NCT07234357","Sensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia","Sensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia (SENSE)","SENSE","Inclusion Criteria:\n\nFor patients:\n\n* Aged 50 years old and above.\n* Confirmed diagnosis of MCI or mild dementia based on clinical records.\n* Has one identified caregiver aged 21 years and above who is willing to provide written informed consent for his\u002Fher own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours\u002Fday ≥3 days\u002Fweek; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study intervention.\n\nFor caregivers:\n\n* Aged 21 years old and above.\n* Willing and able to provide written informed consent\n* Identified as the caregiver for recruited patient in this study can read, understand, and speak the designated language at the study site; either lives with the recruited patients or sees the patient for ≥2 hours\u002Fday ≥3 days\u002Fweek.\n* Agrees to accompany the patient to each study visit; and can verify daily compliance with study intervention.\n\nExclusion Criteria:\n\nFor patients:\n\n* Olfactory impaired\u002Fdysfunctional.\n* Known or suspected hypersensitivity\u002Fallergy to essential oils or any components of the formulations.\n* Has Reactive Airway Disease (e.g, Asthma).\n* Participant without a caregiver.\n* Pregnant, breastfeeding, or intending to conceive during study period.\n\nFor caregivers:\n\n* Physically or mentally incapable of providing verbal \u002F written consent\n* Does not have regular or meaningful contact with the participant (e.g. less than 2 hours\u002Fday or less than 3 days\u002Fweek).\n* Not able to follow patient to each study visit.",{"count":57,"type":23},[59],"To determine if diffusion aromatherapy exposure to an essential oil blend can potentially improve mild cognitive impairment\u002Fmild dementia symptoms and relieve caregiver stress.\n\nThis study also allows us to gauge the willingness of elderly patients in complying with long-term aromatherapy treatments.",[30,639],"Mild Dementia",[641,642,643,328,639,118,120,644,645,646],"Aromatherapy","Diffusion Aromatherapy","Essential Oils","Caregiver Stress","Elderly Compliance","Caregiver","2026-07-15",{"date":562,"type":39},{"date":650,"type":39},"2026-06-09",{"date":652,"type":23},"2027-11",{"name":654,"class":80},"National Cancer Centre, Singapore",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":18,"minAge":322,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":24,"phases":664,"briefSummary":665,"conditions":666,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":47},"100547082","a-feasiblity-study-of-green-activity-program-for-people-living-with-memory-challenges-100547082","NCT06403345","A Feasiblity Study of Green Activity Program for People Living With Memory Challenges","GAP","Inclusion Criteria:\n\n* 45 years or older\n* Has memory challenges or difficulties thinking\n* Have access and ability to respond to the telephone (mobile or landline)\n\nStudy partner\n\n* 18 years or older\n* Speaks Spanish or English\n* Identified by the PLMC as a person they feel comfortable with who they would like to join them in the study. The study partner's participation is based on level of support needed for the PLMC.\n\nOutdoor activity professionals\n\n* 18 years or older\n* at least 1 year experience providing outdoor activities\n\nExclusion Criteria:\n\nParticipants living with memory challenges will be excluded if they do not meet inclusion criteria or if they indicate any of the following on the 2023 Physical Activity Readiness Questionnaire + (PAR-Q+) :\n\n* Heart failure or, difficulty controlling Coronary Artery Disease, Diagnosed Abnormality of Heart Rhythm, or other cardiovascular condition.\n\n  * If they report difficulty controlling CAD, Diagnosed abnormality of heart rhythm they will be excluded.\n  * If they endorse a diagnosis of heart failure, AND report symptoms greater than NYHA Functional Classification Stage I: \"No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath,\" they will be excluded. Research assistants will be trained to ask about these symptoms during usual activities of daily living.\n  * If their doctor has told them not to participate in physical activity due to their heart condition or another medical condition, they will be excluded.\n* Cancer and are in an active cycle of infusion chemotherapy or daily radiation treatments.\n\n  * People with cancer whose treatment regimen does not impact their day to day routines (e.g.-oral chemotherapy agents) may participate. Research assistants will be trained to ask about the impact of cancer and cancer care on day to day activities and physical activity.\n  * If their doctor has told them not to participate in physical activity due to their cancer or cancer treatment or another medical condition, they will be excluded.\n* Experienced a black out, fainted, or lost consciousness as a result of a head injury in the past 12 months.\n* Often experienced signs and symptoms of low blood sugar (hypoglycemia) following exercise and\u002For daily activities.\n* 2 or more hospitalizations in 6 months",{"count":663,"type":23},40,[59],"The purpose of this study is to test the Green Activity Program that was designed with people living with memory challenges and their study partners to see if it can be done and if they enjoy the program. \"Green activities\" are nature activities that the person enjoys and can be done with other people or pets. For example, dog walking, hiking, outdoor yoga, and gardening are all green activities. The purpose of the program is to help people living with memory challenges participate in nature activities they enjoy. The goal of the program is to help people stay active and improve their health and well-being.",[30,63,667],"Subjective Cognitive Decline (SCD)","2026-07-14",{"date":647,"type":39},{"date":671,"type":39},"2024-07-17",{"date":673,"type":23},"2026-12-30",{"name":314,"class":80}]